Growth Hormone Peptides, Bear Serum, and Prostate Growth | The Gillett Health Podcast #6

About this video

This Q&A centers on growth hormone and growth hormone–releasing peptides, prostate concerns, and longevity trade-offs. Gillett describes growth hormone signaling as broad and non-specific, acting through IGF-1 across many tissues including the prostate, and he questions long-term unsupervised use by people without a deficiency. He discusses contexts he considers more defensible, such as short-term recovery support in older or frailer patients, alongside risks of excess growth signaling. The hosts also explore a study on hibernating bear serum and muscle preservation as early, in-vitro science, and close by examining how expectation and warning labels can amplify reported side effects, using statin research as an example.

Key takeaways

• Gillett frames growth signaling as a balance, not something to maximize indefinitely
• Prostate and metabolic effects deserve monitoring when growth pathways are stimulated
• Bear-serum muscle findings are presented as preliminary cell research, not a therapy
• Expectation can inflate perceived side effects — compare treatment and placebo rates
• Anecdotal joint or sleep benefits do not establish a deficiency, the hosts argue

Episode details: published August 15, 2022 · 1K views · 46:40 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.

← Previous: What Are Growth Hormone Peptides? | The Gillett Podcast #6 · Next: Gillett Health Q&A | The Gillett Health Podcast #8 →

All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)